Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.
Key points in the video:
- details of ANP’s recent $A7.6m capital raising and how it plans to use the money
- what the company’s share registry looks like post this placement
- 2021 and what it holds for Antisense
- the company’s plans with regard to overseas listings
